Researchers at the University of California, Davis have identified a unique protein target for the development of therapies for advanced prostate cancers.
There is a strong need for the development of therapies for the treatment of advanced prostate cancers (PCa). Current therapeutics target either the androgen receptor (AR) or the androgen biosynthesis enzymes. These treatments are subject to cancer resistance and together give only a few months of overall survival benefit in a portion of PCa patients.
Researchers at the University of California, Davis, have identified a unique protein target, ROR-γ, for the development of effective PCa therapeutics. By targeting ROR-γ, two important PCa tumor-driving pathways are inhibited. The inhibitors have been synthesized and verified in vitro in PCa cells and in vivo in xenograft mouse model with human PCa.This mechanism of action (MOA) has the potential to be an effective target for therapy resistant cancers and offers an improved therapeutic approach compared to currently available therapies.
|United States Of America||Published Application||20180085348||03/29/2018||2015-539|
|Patent Cooperation Treaty||Published Application||2016145298A1||09/15/2016||2015-539|